Product Overview

AOP Orphan's focus is on rare and special diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Intensive Care. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to rare and special diseases. 

Neurology & Metabolic Disorders

Ocaliva®

Ocaliva® is indicated for the treatment of primary biliary cholangitis (also known to as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.

Drug Facts
Active Ingredient
Obeticholic acid
Intensive Care

Raploc®

Raploc® is indicated for supraventricular tachycardia and for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable.

Drug Facts
Active Ingredient
Landiolol Hydrochloride
Cardiology & Pulmonology

Tadalafil AOP

Tadalafil is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity.

Drug Facts
Active Ingredient
Tadalafil
Neurology & Metabolic Disorders

Tetmodis®

Tetmodis® is used as symptomatic therapy in the treatment of hyperkinetic motor disorders in Huntington’s disease. Tetrabenazine is also used in etiologies such as tardive dyskinesia, tics and dystonia.

Drug Facts
Active Ingredient
Tetrabenazine
HematoOncology

Thromboreductin®

Thromboreductin® is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients.

Drug Facts
Active Ingredient
Anagrelide
Neurology & Metabolic Disorders

Wakix®

Wakix® is indicated in adults for the treatment of narcolepsy with or without cataplexy.

Drug Facts
Active Ingredient
Pitolisant